Teva Pharmaceutical Industries
TEVATeva Pharmaceutical Industries Ltd. is a multinational pharmaceutical company that develops, manufactures, and markets generic medicines, specialty pharmaceuticals, and active pharmaceutical ingredients worldwide. As one of the largest generic drug companies globally, Teva serves patients in approximately 60 countries with a portfolio of over 3,500 products across a wide range of therapeutic areas. The company has faced significant financial challenges in recent years but continues to maintain its position as a major player in the global pharmaceutical industry through its extensive manufacturing network and R&D capabilities.
TEVA · Stock Price
Historical price data
AI Company Overview
Teva Pharmaceutical Industries Ltd. is a multinational pharmaceutical company that develops, manufactures, and markets generic medicines, specialty pharmaceuticals, and active pharmaceutical ingredients worldwide. As one of the largest generic drug companies globally, Teva serves patients in approximately 60 countries with a portfolio of over 3,500 products across a wide range of therapeutic areas. The company has faced significant financial challenges in recent years but continues to maintain its position as a major player in the global pharmaceutical industry through its extensive manufacturing network and R&D capabilities.
Technology Platform
Global generic pharmaceutical development and manufacturing platform with expertise in complex generics, biosimilars, and specialty formulations across multiple therapeutic areas.
Pipeline
9| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Laquinimod + Placebo | Relapsing Remitting Multiple Sclerosis | Phase 2 | |
| TV-1106 + somatropin | Growth Hormone-Deficiency | Phase 2 | |
| 40 mg glatiramer acetate + Placebo | Amyotrophic Lateral Sclerosis | Phase 2 | |
| Hydroxychloroquine (HCQ) + Azithromycin (Azithro) + Placebo ... | COVID-19 | Phase 2 | |
| cytarabine + omacetaxine mepesuccinate + decitabine | Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Phase 2 |
Opportunities
Risk Factors
Competitive Landscape
Teva competes in a highly competitive global generics market against companies like Sandoz, Viatris, and Sun Pharma, while differentiating through its scale, complex generics capabilities, and specialty CNS portfolio including multiple sclerosis and movement disorder treatments.